135 related articles for article (PubMed ID: 29798417)
1. [Expression and clinical significance of Nrf2 and ERK pathway in papillary thyroid carcinoma].
Chen YM; Wei L; Lin X; Zhang WJ; Wu JF; Xue G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(12):941-945. PubMed ID: 29798417
[No Abstract] [Full Text] [Related]
2. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].
Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract][Full Text] [Related]
4. NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.
Zhang TT; Qu N; Sun GH; Zhang L; Wang YJ; Mu XM; Wei WJ; Wang YL; Wang Y; Ji QH; Zhu YX; Shi RL
Int J Oncol; 2018 Aug; 53(2):685-693. PubMed ID: 29901070
[TBL] [Abstract][Full Text] [Related]
5. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
6. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma.
Wei X; Zhang Y; Yu S; Li S; Jiang W; Zhu Y; Xu Y; Yang C; Tian G; Mi J; Bergquist J; Zhao M; Song F
Biochem Biophys Res Commun; 2018 May; 499(2):338-344. PubMed ID: 29574154
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
8. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
[No Abstract] [Full Text] [Related]
12. [Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma].
Zhang Z; Bai Y; Li P; Zhao J; Wang Y; Sun L; Tang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 27(22):1265-8. PubMed ID: 24616987
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
[TBL] [Abstract][Full Text] [Related]
16. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 as a novel diagnostic biomarker for papillary thyroid carcinoma.
Wang Z; Li J; Liu Z; Yue L
Eur J Histochem; 2023 Mar; 67(2):. PubMed ID: 36951264
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
Hao Y; Jin C; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.
Zhang J; Wang P; Dykstra M; Gelebart P; Williams D; Ingham R; Adewuyi EE; Lai R; McMullen T
J Pathol; 2012 Oct; 228(2):241-50. PubMed ID: 22744707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
